Asenjo AJA

Language: Spanish
References: 15
Page: 417-423
PDF size: 261.23 Kb.

ABSTRACT

Background: chronic diseases as they evolve require the use of several medications for their control. This use increases the longer they have been since their diagnosis, a situation that can have a negative impact on the health of patients due to drug interactions.
Objective: to associate polypharmacy with the main chronic diseases in patients treated in a Peruvian provincial hospital.
Methods: a descriptive, retrospective and cross-sectional study was carried out, carried out in September 2022, with 159 patients with type 2 diabetes and arterial hypertension treated at the José Hernán Soto Cadenillas Hospital in Chota. Characterization data, drugs consumed and chronic diseases were obtained from the Nominal Register System of patients enrolled in the Hospital. The independent analysis of variables was done using absolute and relative frequencies, 95 % confidence intervals, mean, standard deviation, minimum, maximum and the association between variables with chi-square of independence, with p < 0.05 of statistical significance.
Results: 72.3 % of patients were women, their mean age was 68.6 years, the consumption of 4 drugs was the average for the comorbidity of type 2 diabetes and arterial hypertension, followed by 3 drugs in arterial hypertension, which represented polypharmacy for both cases (30.2 and 23.8 %, respectively). There is a significant statistical association between suffering from chronic disease and polypharmacy (p = 0.002).
Conclusion: most patients consume 3 or more drugs, especially if they suffer from both diseases, so polypharmacy is significantly associated with the occurrence of chronic diseases.

REFERENCES

1. Rieckert A, Trampisch US, Klaaßen R, Drewelow E, Esmail A, Johansson T, et al. Polypharmacy in older patients with chronic diseases: a cross-sectional analysis of factors associated with excessive polypharmacy. BMC Fam Pract. 2018;19(1):113.

2. Matthias AT, Fernando GV, Somathilake BG, Prathapan S. Predictors and patterns of polypharmacy in chronic diseases in a middle-income country. Int J Physiol Pathophysiol Pharmacol. 2021;13(6):158-65.

3. Hughes CM. One size fits all? How to optimize the prescribing of appropriate polypharmacy in chronic diseases, using a behavioral approach - a United Kingdom perspective. Expert Rev Clin Pharmacol. 2022;15(5):497-9.

4. Remelli F, Ceresini MG, Trevisan C, Noale M, Volpato S. Prevalence and impact of polypharmacy in older patients with type 2 diabetes. Aging Clin Exp Res. 2022;34(9):1969-83.

5. Diaconu CC, Cozma MA, Dobrica EC, Gheorghe G, Jichitu A, Ionescu VA, et al. Polypharmacy in the Management of Arterial Hypertension-Friend or Foe? Medicina (Kaunas). 2021;57(12):1288.

6. Alwhaibi M. Potentially Inappropriate Medications Use among Older Adults with Comorbid Diabetes and Hypertension in an Ambulatory Care Setting. J Diabetes Res. 2022;15(9):1511.

7. Pietraszek A, Agrawal S, Drózdz M, Makuch S, Domanski I, Dudzik T, et al. Sociodemographic and Health-Related Factors Influencing Drug Intake among the Elderly Population. Int J Environ Res Public Health. 2022;19(14):8766.

8. Adem L, Tegegne GT. Medication Appropriateness, Polypharmacy, and Drug-Drug Interactions in Ambulatory Elderly Patients with Cardiovascular Diseases at Tikur Anbessa Specialized Hospital, Ethiopia. Clin Interv Aging. 2022;17(1):509-17.

9. Kwak MJ, Chang M, Chiadika S, Aguilar D, Avritscher E, Deshmukh A, et al. Healthcare Expenditure Associated With Polypharmacy in Older Adults With Cardiovascular Diseases. Am J Cardiol. 2022;169(1):156-8.

10. Paredes H. Los estilos de vida y características sociales de los pacientes con diabetes mellitus tipo 2 Hospital José Hernán Soto Cadenillas Chota -2015[Internet]. Perú:Hospital José Soto Cadenillas de Chota;2015[citado 18/9/2022]. Disponible en: Disponible en: https://repositorio.unc.edu.pe/bitstream/handle/20.500.14074/920/TESIS%20HILDA%20PAREDES%20SANCHEZ.pdf?sequence=4&isAllowed=y 10. .

11. Klinedinst TC, Nelson TL, Gloeckner GW, Malcolm MP. Depression and polypharmacy are risk factors for activity limitation in type 2 diabetes. Chronic Illn. 2022;18(2):320-9.

12. Rosli NA, Mazapuspavina MY, Ismail Z, Ismail NE. Relationship of Self Efficacy in Medication Understanding with Quality of Life among Elderly with Type 2 Diabetes Mellitus on Polypharmacy in Malaysia. Int J Environ Res Public Health. 2022;19(5):3031.

13. Mader JK, Aberer F, Drechsler KS, Pöttler T, Lichtenegger KM, Köle W, et al. Medication errors in type 2 diabetes from patients' perspective. PLoS One. 2022;17(4):e0267570.

14. Lean M, McCombie L, Xin Y. Forget polypharmacy for type 2 diabetes! Weight management is a better investment. Nephrol Dial Transplant. 2022;37(5):844-6.

15. Mecca MC, Zenoni M, Fried TR. Primary care clinicians' use of deprescribing recommendations: A mixed-methods study. Patient Educ Couns. 2022;105(8):2715-20.